Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px
Document › Details

NuPharm Group. (7/3/18). "Press Release: NuPharm Group Announces the Acquisition of Laboratoire Biodim in France". Paris.

Region Region Europe
Organisations Organisation Laboratoire Biodim (FR)
  Today Neuraxpharm France
  Group NuPharm (Group)
  Organisation 2 Pharma Omnium International (FR)
  Today Pharma Omnium (Group)
  Group Pharma Omnium (Group)
Products Product CNS drug (neurological drug)
  Product 2 private equity
Index term Index term Pharma Omnium–NuPharm: investment, 201807 acquisition €na of Laboratoire Biodim from Pharma Omnium
Person Person Walz, Stephan (Invent Pharma / Neuraxpharm 201706 CEO)

NuPharm Group, a leading European specialty pharma company focused on the treatment of central nervous system (“CNS”) disorders, has today announced that it has completed the acquisition of the French specialty pharma company Laboratoire Biodim (“Biodim”) from Pharma Omnium International, a company owned by Weinberg Capital Partners since 2006.

Located in Paris, Biodim was the commercial division of Pharma Omnium International. The company focuses on the sale and marketing of branded pharmaceutical products mainly used to treat anxiety disorders, including leading brands such as SERESTA® and TEMESTA®.

Biodim, which will be renamed Neuraxpharm France, will become the newest member of NuPharm Group, expanding its European footprint directly into its fifth country after Germany, Spain, Italy and Poland. The Group has one of the largest drug portfolios for treating central nervous system diseases, with more than 100 molecules. Neuraxpharm France will benefit from this wide and specialised portfolio which has been strategically developed to meet the needs of all CNS patients.

“We are delighted to have Biodim join the NuPharm family as this marks the entrance of our Group into another major European market. With this acquisition and others to come, we continue to move forward with our vision to become the European leader in CNS pharmaceuticals”, said Stephan Walz, Chief Executive Officer of NuPharm Group.

The terms of the transaction were not disclosed.

About NuPharm Group

NuPharm Group, a European leader in the treatment of diseases related to the central nervous system, is the strategic combination of five (5) leading specialty pharmaceutical companies: Neuraxpharm (Germany and Poland), Qualigen (Spain), FB Health (Italy) and Laboratorios Lesvi and Inke (Spain). The Group is backed by Funds advised by Apax Partners, who formed the Group in 2016.

NuPharm develops and markets branded, generic and nutraceutical pharmaceutical products by offering a wide range of proven, differentiated and affordable CNS treatment options to healthcare professionals and industry partners.

With an international presence in more than 50 countries, the Group also manufactures finished dosage forms (FDF) and active pharmaceutical ingredients (API) for CNS and respiratory indications.

About Weinberg Capital Partners

Weinberg Capital Partners, founded in 2005 at the initiative of Serge Weinberg and based in Paris, is a private equity and real estate investment firm specialising in majority leveraged buy-out transactions and industry consolidation in mature, growth capital and mid-market companies located in France and Southern Europe.

For more information:

Greenbrook Communications
James Madsen
Tel.: +44 (0) 20 7952 2000

Laura García
Tel.: +34 93 410 60 99

Record changed: 2023-06-05


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for NuPharm (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px

» top